ClinicalTrials.gg
Not yet recruitingNCT06639516Updated Feb 6, 2025

Therapeutic Effect of Bifidobacterium Longum in Patients with Acute Pancreatitis: a Randomized, Double-Blind, Placebo-Controlled Trial

An interventional study of Bifidobacterium longum and Placebo in Acute Pancreatitis, sponsored by The First Affiliated Hospital of Nanchang University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by The First Affiliated Hospital of Nanchang University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies in Pancreatitis with a site in China — 40 open to participants now, 44 under way, 2 of them phase 3. Pancreatitis · China.

Planned enrollment
52nd of 75
60 · median 110
Started
2025
with 16 others
No phase
48 of 104
16 open now
Primary completion
2025-12
later than 6 of 43 live
Registered
69th of 104
by date
Lead sponsor
7 of 104
The First Affiliated Hospital of Nanchang University

Among the 104 studies in Pancreatitis with a site in China, this one is the 52nd largest by planned enrollment of the 75 interventional ones that give a count, is one of 17 that started in 2025, is one of 48 with no phase, reaches primary completion later than 6 of the 43 other live ones, and was the 69th registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

40 of the 104 studies in Pancreatitis with a site in China are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Pancreatitis with a site in China, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to investigate the impact of Bifidobacterium longum(BL) on the clinical prognosis of patients with acute pancreatitis(AP), to analyze the correlation between BL and intestinal barrier function, as well as the gut microbiota, and to observe adverse reactions and risks in patients with AP after the use of BL.

Participants will be randomly assigned to two groups: the intervention group and the control group. They will receive:

  • Intervention group: Standard clinical treatment + BL capsules (10\^10 CFU), twice a day, for a total of 14 days;
  • Control group: Standard clinical treatment + placebo capsules, for a total of 14 days.

A total of 60 patients will be included in this study.

Read the detailed description

Rationale:The impairment of the intestinal mucosal barrier in patients with acute pancreatitis (AP) plays a crucial role in the progression to severe AP(SAP). Our previous research found that the early gut microbiota structure of AP patients is significantly different from that of healthy individuals, characterized by a marked increase in the relative abundance of conditional pathogens such as Escherichia coli and Shigella, while beneficial bacteria that produce short-chain fatty acids, such as Bifidobacterium, are significantly reduced, especially in patients with SAP. Bifidobacterium longum (BL), a well-known probiotic, has been used to treat a variety of diseases. In our previous animal experiments, we found that BL could alleviate pancreatic damage and inflammatory responses in AP mice and regulate the balance of the gut microbiota. Based on these findings, this study aims to assess the impact of BL on the clinical prognosis of AP patients through a randomized controlled trial, in order to provide a scientific basis for the application of BL in the treatment of AP and to further explore its potential clinical value.

Objective: The purpose of this clinical trial is to investigate the impact of BL on the clinical prognosis of patients with AP, to analyze the correlation between BL and intestinal barrier function, as well as the gut microbiota, and to observe adverse reactions and risks in patients with AP after the use of BL.

Study design: Single-center, randomized, double-blind, placebo-controlled study.

Study population:60 adult patients with acute pancreatitis. Intervention: The intervention group receives standard clinical treatment plus BL capsules (10\^10 CFU), twice a day, for a total of 14 days; the control group receives standard clinical treatment plus placebo capsules, for a total of 14 days.

Main study parameters/endpoints: The primary endpoint is the number of days without SIRS within 14 days; the secondary endpoints include infectious complications (including fungal infections), parameters related to systemic inflammatory response, intestinal barrier function and gut microbiota composition, indicators related to recovery of intestinal function, antibiotic use, laboratory-related indicators, and clinical outcomes.

Safety: Throughout the study (or afterwards), treatment-emergent adverse events (TEAEs) were recorded, including gastrointestinal adverse reactions (abdominal pain, nausea, vomiting, bloating, or diarrhea) and allergic reactions, and adverse events that led to discontinuation of the study drug were documented.

03

Conditions studied

  • Acute Pancreatitis

Browse trials for

Keywords

  • acute pancreatitis
  • Probiotics
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 year;
  2. The diagnosis of acute pancreatitis according to the revised Atlanta classification;
  3. The onset time of acute pancreatitis is within 48 hours;
  4. APACHE II score of ≥8, or C-reactive protein \> 150 mg/L, or SIRS score of ≥3;
  5. Signed the .

Exclusion criteria

Exclusion Criteria:

  1. Within 48 hours of onset, there is multi-organ failure;
  2. Use of probiotics within the last month;
  3. Pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP);
  4. Intra-operative diagnosis;
  5. Infection/sepsis caused by a second disease;
  6. ;
  7. patients;
  8. Pregnancy and/or lactation;
  9. Allergy to Bifidobacterium longum.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Bifidobacterium longum capsules (10\^10 CFU) twice daily for 14 days

    Dietary Supplement: Bifidobacterium longum · Combination Product: Standard clinical treatment

  • Placebo comparator
    Placebo group

    Placebo capsules twice daily for 14 days

    Dietary Supplement: Placebo · Combination Product: Standard clinical treatment

Interventions

  • Dietary supplementBifidobacterium longum

    Bifidobacterium longum

  • Dietary supplementPlacebo

    Placebo

  • Combination productStandard clinical treatment

    Fasting, gastrointestinal decompression, rehydration, inhibition of pancreatic fluid and pancreatic enzyme secretion, improvement of microcirculation, and support of organ function if organ dysfunction occurs at a later stage (mechanical ventilation, continuous renal replacement therapy, and the use of vasoactive drugs).

06

What researchers measure

Primary outcomes

  1. The number of days without SIRS within 14 days

    Patients were randomized into the study group and remained free of SIRS up to 14 days after enrollment, with the total number of SIRS-free days counted

    Time frame: From randomization to 14 days after treatment

Secondary outcomes

  1. Infectious complications

    The occurence of infected pancreatic necrosis, bacteremia, pneumonia, urosepsis, and/or infected ascites,including fungal infections

    Time frame: During the whole study period including follow-up of 90 days

  2. Intestinal barrier function

    Plasma D-lactate(D-lac)

    Time frame: Through study completion, an average of 1 year

  3. Intestinal barrier function

    Diamine oxidase activity(DAO)

    Time frame: Through study completion, an average of 1 year

  4. Intestinal barrier function

    Plasma endotoxin levels

    Time frame: Through study completion, an average of 1 year

  5. Gut microbiota composition

    Fecal samples were collected from patients prior to the start of treatment, as well as on days 3, 7, and 14 after treatment. Subsequently, DNA was extracted from the feces, and the DNA was fragmented by Covaris M220 to screen for fragments of approximately 350 bp to be constructed into paired-end (Paired-End) DNA libraries. Next, libraries were constructed using NEXTFLEX Rapid DNA-Seq. Finally, these libraries were subjected to macro-genomic sequencing for in-depth analysis of microbial community structure and function in the samples.

    Time frame: Baseline , 3 days,7 days and 14 days of treatment

  6. Systemic inflammatory response parameters (SIRS)

    The incidence of persistent SIRS (lasting ≥48 hours)

    Time frame: Through study completion, an average of 1 year

  7. Systemic inflammatory response parameters (SIRS)

    Trends in SIRS score changes

    Time frame: Through study completion, an average of 1 year

  8. Systemic inflammatory response parameters (SIRS)

    Trends in CRP level changes

    Time frame: Through study completion, an average of 1 year

  9. Gut function recovery-related indicators

    Improvement in abdominal signs

    Time frame: Through study completion, an average of 1 year

  10. Antibiotic usage

    The number of days of antibiotic use

    Time frame: Through study completion, an average of 1 year

  11. Mortality

    Occurence of death

    Time frame: During the whole study period including follow-up of 90 days

  12. (New onset) transient/persistant (multiple) organ failure

    The occurence of (new onset) transient/persistant (multiple) organ failure

    Time frame: During the whole study period including follow-up of 90 days

  13. Disease severity according to the revised Atlanta Classification

    Disease severity according to the revised Atlanta Classification

    Time frame: During the whole study period including follow-up of 90 days

  14. Length of hospital and/or ICU stay

    Measured in days

    Time frame: Through study completion, an average of 1 year

  15. The need (and number of) for surgical, endoscopic or radiologic interventions

    The need (and number of) for surgical, endoscopic or radiologic interventions

    Time frame: During the whole study period including follow-up of 90 days

  16. Readmissions

    The occurrence and number of readmissions

    Time frame: During the whole study period including follow-up of 90 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Dec 2025, 9 months later.

Of 92 non-industry interventional studies with no phase under Pancreatitis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 9 months is below that.

Counting every sponsor, half of 95 studies reached it within 32 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2024
First posted
Oct 15, 2024
StartEst.
Feb 15, 2025
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 1, 2025
Last update
Feb 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06639516
Lead sponsor
The First Affiliated Hospital of Nanchang University
Responsible party
Lingyu Luo (Professor, The First Affiliated Hospital of Nanchang University) — Principal investigator
First posted
Oct 15, 2024
Start date
Feb 15, 2025 (estimated)
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Feb 6, 2025

Study contacts

yin zhu, PhD
Contact
ndyfy01977@ncu.edu.cn
+8613970847464
Cong He, PhD
principal investigator · The First Affiliated Hospital of Nanchang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bifidobacterium longum

Start the discussion